News
Discover how inflammation peptides are revolutionising our understanding of immune regulation, offering new avenues for ...
6d
AZoLifeSciences on MSNSimple Peptides Mimic Natural Protein Protection to Revolutionize Biomolecule Stability
A new study from researchers at the Advanced Science Research Center at the CUNY Graduate Center (CUNY ASRC) reveals that extremely simple peptides can mimic a biological process that protects ...
Californian biotech startup Geltor has secured fresh funding to expand its biodesigned polypeptides, including precision-fermented collagen, to new markets.
6d
News Medical on MSNStudy offers a promising new approach to stabilizing biomolecules
A new study from researchers at the Advanced Science Research Center at the CUNY Graduate Center (CUNY ASRC) reveals that extremely simple peptides can mimic a biological process that protects ...
ProteinQure's PQ203, a novel peptide drug conjugate, gains FDA fast track designation for advanced triple-negative breast ...
Explores Behemoth Labz GLP‑1 nasal formulation's structural design, analytic insights, and intranasal incretin research relevance in preclinical metabolic ...
FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlin ...
Phase 2 topline data from Avail trial expected in Q3 2025. Topline results from the Phase 2 Avail trial of canvuparatide, a potential long-acting, once-weekly parathyroid hormone (PTH) peptide prodrug ...
NEW YORK – ProteinQure said Thursday that the US Food and Drug Administration and Health Canada cleared it to begin a Phase I trial of its lead candidate, the peptide-drug conjugate PQ203, in ...
FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatmentSignifi ...
Target the signs of ageing with this "game changing" dual-function serum that is at its cheapest price on Amazon.
A new study demonstrates the significant impact of an oncology-trained pharmacist in reducing ADRs in a hematology-oncology clinic.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results